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Nuclear AURKA acquires kinase-independent
transactivating function to enhance breast cancer
stem cell phenotype
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Centrosome-localized mitotic Aurora kinase A (AURKA) facilitates G2/M events. Here we
show that AURKA translocates to the nucleus and causes distinct oncogenic properties in
malignant cells by enhancing breast cancer stem cell (BCSC) phenotype. Unexpectedly, this
function is independent of its kinase activity. Instead, AURKA preferentially interacts with
heterogeneous nuclear ribonucleoprotein K (hnRNP K) in the nucleus and acts as a
transcription factor in a complex that induces a shift in MYC promoter usage and activates
the MYC promoter. Blocking AURKA nuclear localization inhibits this newly discovered
transactivating function of AURKA, sensitizing resistant BCSC to kinase inhibition.
These ﬁndings identify a previously unknown oncogenic property of the spatially deregulated
AURKA in tumorigenesis and provide a potential therapeutic opportunity to overcome kinase
inhibitor resistance.
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T
he oncogenic activation of kinases through mutation1 and
ampliﬁcation2 often leads to constitutively active kinase
activity and cancer development3. This characteristic
renders them addicted to constitutive kinase activation and
thereby susceptible to kinase inhibition by small targeted
molecules4. Despite the success of molecular targeted therapies
that inhibit kinase activity in multiple cancers such as chronic
myelogenous leukemia5 and lung cancer6, the development of
resistance to kinase inhibition is inevitable, leading to cancer
recurrence7. Missense mutations in the catalytic core of kinases
account for the majority of clinically observed drug resistance
cases8. Although new small molecule inhibitors can tolerate
diverse mutations at the catalytic core, the blockage of kinase
activation alone is often not sufﬁcient to attain maximum
therapeutic efﬁcacy9.
Emerging evidence indicates that current therapeutic inhibitors
do not effectively eliminate cancer stem cells (CSCs), thereby
leading to drug resistance10. Several mechanisms of drug
resistance have been proposed in CSCs, including tumour
microenvironment nursing CSCs11, metabolic pathway
alterations12 and epigenetic alterations13. However, the
mechanisms that underlie therapeutic kinase inhibitor
resistance remain elusive and require further elucidation.
Activation of Aurora kinase A (AURKA) plays an essential role
in the control of mitosis progression, centrosome maturation/
separation and mitotic spindle function14. AURKA has attracted
a great deal of interest as a potential therapeutic target due to its
overexpression in cancers14. Inhibitors of Aurora kinases, such as
MLN8237 and PHA-739358, have been developed15, but were
found to be moderately effective in preclinical and clinical
studies15,16. These data suggest that a kinase-independent
mechanism contributes to inhibitor insensitivity. There is
emerging evidence to suggest that AURKA also promotes
cancer development through mechanisms independently of its
kinase activity17. Moreover, AURKA localizes to structures other
than the mitotic apparatus during interphase to regulate neurite
elongation and ciliary resorption, suggesting that AURKA
possesses functions beyond its kinase activity18, and that
inhibition of Aurora kinase alone may not be sufﬁcient to
repress AURKA oncogenic functions.
Previous study shows that the tumour tissues display nuclear
AURKA staining19, which predicts a poorer clinical outcome in
ovarian cancer20. Conversely, cytoplasmic localized AURKA
consistently fails to enhance the H-Ras-induced transformation
in BALB/c 3T3 A31-1-1 cells21. These studies suggest an
oncogenic role of nuclear AURKA that might be independent
of its kinase activity. Here we demonstrate that AURKA displays
a kinase-independent function in the nucleus to activate theMYC
promoter in cooperation with hnRNP K, enhancing the breast
CSC phenotype.
Results
Nuclear AURKA enhances breast CSC phenotype. We ﬁrst
examined cytoplasmic and nuclear expression of AURKA in
breast cancer and adjacent normal tissues (Fig. 1a). AURKA was
detected in the cytoplasm in normal breast tissue. In contrast,
AURKA was also highly expressed in the nuclear fraction of
breast cancer tissue. Consistent with this, a similar expression
pattern of nuclear AURKA was observed with immuno-
histochemistry (IHC) staining (Fig. 1b) and in the nuclear
fraction of all cancer cells lines tested (Supplementary Fig. 1a).
The cytoplasmic AURKA level was lower in breast cancer cells
compared with the non-transformed MCF-10A cells. Immuno-
ﬂuorescence staining (Supplementary Fig. 1b–f) of AURKA
showed results similar to those of both immunoblotting
(Supplementary Fig. 1a) and IHC (Fig. 1b). These data indicated
that the nuclear localization of AURKA would be important
during cancer development. We found that oncogenic
transformation of primary mouse embryonic ﬁbroblasts by
overexpressing K-Ras (G12V mutant) or H-Ras (G12V mutant;
Fig. 1c left panel) increased both cytoplasmic and nuclear
AURKA expression (Fig. 1c right panel). Importantly, the ratio of
nuclear/cytoplasmic AURKA was signiﬁcantly increased in
Ras-transformed cells compared with the wild-type (WT)
counterpart (Fig. 1c right panel).
Previous studies have established that overexpression of
AURKA causes drug resistance22–24, promotes metastases25,26
and predicts poor prognosis for breast cancer27,28. We next
investigated whether nuclear AURKA is involved in the regulation
of breast CSC (BCSC) phenotype. On AURKA depletion (Fig. 1d
left panel), the putative BCSC CD24low/CD44high cell population
was signiﬁcantly reduced in all breast cancer cell lines (Fig. 1d
right panel). Conversely, CD24low/CD44high population was
signiﬁcantly increased following overexpression of AURKA
(Fig. 1e). To further conﬁrm this, we analysed BCSC by
evaluating their aldehyde dehydrogenase activity29. Similarly,
the ratio of ALDEFLUOR (þ ) population was positively
correlated with the expression of AURKA (Supplementary
Fig. 1g,h). We also performed gene set enrichment analysis
(GSEA) and found that cells expressing low levels of AURKA
showed a signiﬁcant enrichment of genes that are downregulated
in the CD24low/CD44high-sphere population (Fig. 1f). We next
investigated the role of nuclear localized AURKA in enhancing
BCSC phenotype. AURKA was fused with the hormone-binding
domain of oestrogen receptor (ER) via nuclear export sequence
(NES)21 and was abbreviated as AER (Fig. 1g upper panel).
Fusion with ER did not signiﬁcantly affect the kinase activity of
AURKA, as indicated by expression of p-p53 (S315) and
p-histone H3 (S10)30,31 (Supplementary Fig. 1i). On 4-
hydroxytamoxifen (OHT) stimulation, AER re-localized to the
nuclear fraction (Supplementary Fig. 1j,k). The CD24low/
CD44high population was markedly suppressed following the
depletion of endogenous AURKA by small interfering RNA
(siRNA) and the empty ER vector could not rescue this cell
population in either the presence or the absence of OHT
(Supplementary Fig. 1l and Fig. 1g lower panel). Interestingly,
expression of cytoplasmic AURKA (without OHT) also failed to
rescue the loss of the CD24low/CD44high population, whereas the
OHT-induced nuclear-localized AURKA effectively restored the
CD24low/CD44high population (Fig. 1g lower panel). Similar
phenomena were observed in mammosphere culture
(Supplementary Fig. 1m,n and Fig. 1h,i). We also found that
sphere formation in the secondary passage was restored only if
AER was expressed in the nucleus (Supplementary Fig. 1m,n and
Fig. 1h,i). In addition, the cells used for mammosphere culture
and secondary passage proliferated normally in adherent culture
(Supplementary Fig. 1o,p) regardless of the cellular localization of
AER; these results suggested that the observed effects were likely
to be linked to self-renewal.
AURKA displays transcriptional activity. To determine the
transcriptional activity of AURKA, we fused GAL4 DNA-binding
domain (DBD) to AURKA and expressed it in 293T cells with a
luciferase reporter containing GAL4 DNA-binding sites upstream
of a TATA box-containing minimal promoter. Expression of
AURKA (WT)-DBD protein increased reporter activities by
nearly tenfold compared with the vector control (DBD only;
Fig. 2a), suggesting that AURKA transactivates gene expression.
Interestingly, the expression of the KA (kinase active) or KD
(kinase dead) mutants of the AURKA-DBD protein also
increased the reporter activity to levels comparable to that
induced by AURKA (WT)-DBD (Fig. 2a). We further tested the
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Figure 1 | Nuclear AURKA enhances breast cancer stem cell phenotype. (a) Primary cells were extracted from breast cancer tissues and adjacent normal
breast tissues. The cytoplasmic and nuclear protein lysates representing an equal number of cells were subjected to immunoblot (IB) analysis.
(b) Representative IHC staining showing AURKA expression. Images were magniﬁed with a 4 or 40 objective. Scale bar, 50mm. (c) Mouse embryonic
ﬁbroblasts (MEFs) overexpressing K-Ras, H-Ras and the vector control (Vec) were analysed by IB for indicated antibodies (left panel). Cytoplasmic and
nuclear lysates of WT ( )-, vector control (Vec)-, K-Ras- and H-Ras-overexpressed MEFs were subjected to IB analysis (right panel). (d) MDA-MB-231,
SUM149 or BT549 cells were treated with AURKA siRNAs for 96 h. Adherent cells were collected for IB analysis (left panel), CD24/CD44 staining and
CD24low/CD44high population analysis via ﬂow cytometry (right panel). (e) HA-tagged AURKA was overexpressed in MCF-10A, SUM149 and BT549 cells
through lentivirus-mediated gene transfer. Puromycin (1mgml 1) selected cells were collected for IB analysis (left panel), CD24/CD44 staining and
CD24low/CD44high population analysis by using ﬂow cytometry (right panel). (f) Gene expression data acquired from a public database (GEO ID:
GSE23541, the group of AURKAþDox and AURKA-Dox) were subjected to GSEA using the gene expression signature that was downregulated in the
CD24low/CD44high-sphere population. (g) MDA-MB-231 cells were co-transfected with shRNA vector (sh Control or shAURKA) and the overexpression
vector (ER or AER) via lentivirus-mediated gene transfer. Puromycin (1mgml 1) and blasticidin (2mgml 1) double selected cells were subjected to
CD24/CD44 staining and analysis via ﬂow cytometry. (h) Cells derived from g were subjected to mammosphere culture assay (6 days, upper panel) and
the secondary passaging (additional 6 days, lower panel). Scale bar, 100mm. (i) Data from three independent experiments derived from g were used for
quantitative analysis of mammosphere size (diameter, F) and mammosphere number. Left panel shows distribution pattern of mammosphere size from
MDA-MB-231 (Kruskal–Wallis test followed by Dunn’s multiple comparison test, ***Po0.001). Right panel shows the number of mammospheres
(F460 mm). Bars represent the means±s.e.m. of three independent experiments (analysis of variance (ANOVA) followed by least signiﬁcant difference
(LSD) test; *Po0.05, **Po0.01, ***Po0.001).
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transactivation activity of AURKA (WT)-DBD in the presence of
three different Aurora kinase inhibitors (Fig. 2b). In agreement,
inhibition of AURKA kinase activity did not abolish its
transactivating function. Together, these results suggest that
AURKA possesses transactivation activity in a kinase-
independent manner.
We next determined whether AURKA contains transactivating
domains. We identiﬁed three putative nine amino acid transactiva-
tion domains (9aaTAD) in AURKA32 (Fig. 2c) and established their
respective hydrophobicity proﬁles (Supplementary Fig. 2a blue line).
To determine the transactivating activity of each putative 9aaTAD,
the hydrophobic residues at position 6 and/or 7 were substituted with
hydrophilic amino acids (Supplementary Fig. 2a red line)33. Mutation
of the second (M2, A234Q/L244S) but not the ﬁrst (M1, L222S) or
the third (M3, L363A/L364S) 9aaTAD reduced the transactivating
activity of AURKA (Fig. 2d), indicating that the second 9aaTAD is
responsible for the transactivating activity of AURKA.
Nuclear AURKA activates MYC transcription. To identify the
downstream transcriptional targets of AURKA, RNA-sequencing
analysis was performed on paired messenger RNA samples
isolated from AURKA-overexpressed MCF-10A cells and control
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(Supplementary Table 1). Expression of a fraction of all identiﬁed
genes was validated in MCF-10A and MDA-MB-231 cells
(Supplementary Fig. 2b,c). These differentially expressed genes
were then subjected to STRING analysis34. STRING analysis
indicated that the oncogene MYC connected with a portion of
AURKA-modulated genes with high conﬁdence (40.7; Fig. 2e
and Supplementary Table 2) and might function as a hub
molecule. Owing to the role of c-Myc in regulating diverse
cellular functions35, we speculated that MYC might be a critical
downstream target of AURKA that mediates the BCSC-related
function.
We next examined whether AURKA regulates MYC gene
expression at the transcriptional level. MYC mRNA was
downregulated on AURKA depletion by siRNA and enhanced
by the overexpression of AURKA in MDA-MB-231 cells
(Supplementary Fig. 2d,e). Interestingly, WT AURKA, as well
as KA and KD mutants, upregulated MYC mRNA expression at
comparable levels (Supplementary Fig. 2e). Similar observation
was made in BT549 and SUM149 cells (Supplementary Fig. 2f–i).
Although AURKA depletion decreased the basal level of c-Myc,
the half-life of c-Myc was not affected (Supplementary Fig. 2j).
Furthermore, we found that AURKA expression induced the
activity of the MYC promoter (from  2,269 to þ 516;
Supplementary Fig. 2k,l), which was more likely to be dependent
on the nuclear localization of AURKA (Fig. 2f,g) than its kinase
activity (Supplementary Fig. 2l).
We further compared the luciferase reporter activity of the
three mutants and found that the AURKA M2 mutant failed to
increase MYC transcription as compared with M1 and M3
mutants (Fig. 2h and Supplementary Fig. 2m). We then
determined the region of MYC promoter that is required for
AURKA-activated MYC transcription. AURKA failed to activate
transcription at MYC promoter when  352 to  104 region of
MYC promoter was deleted (Fig. 2i). Results from chromatin
immunoprecipitation (ChIP) assays further indicated that
AURKA interacted with  352 to  104 region of MYC
promoter (Fig. 2j). Consistent with these results, the interaction
between AURKA and the MYC promoter was unaffected by the
inhibition of AURKA kinase activity (Fig. 2k).
Nuclear AURKA induces a shift in MYC promoter usage.
The human MYC gene mainly transcripts from its P1 and P2
promoters36. Owing to the role of AURKA in BCSC, we ﬁrst
examined the relative utilization of P1 and P2 in BCSC and non-
BCSC. S1 nuclease protection assay showed that the P1/P2 ratio
was higher in the sphere, which is enriched in BCSC, compared
with cells from adherent culture (Fig. 2l). Furthermore, CD24Low
or side population cells also displayed higher P1/P2 ratio
compared with CD24High or non-side population cells (Fig. 2m
and Supplementary Fig. 2n). We next examined whether nuclear
AURKA regulates the differential utilization of P1 and P2
promoters. As shown in Fig. 2n, nuclear, but not cytoplasmic,
AURKA increased the P1/P2 ratio, inducing a shift in MYC
promoter usage. Consistently, mutation of the second (M2,
A234Q/L244S) AURKA transactivation domain (TAD) abolished
the AURKA-induced shift in MYC promoter usage (Fig. 2o).
AURKA and hnRNP K efﬁciently interact in the nucleus.
We next identiﬁed the proteins that were critical for AURKA-
promoted activation of MYC promoter. We determined the
proteins interacting with AURKA by SILAC37. We searched for
proteins that interacted with AURKA and are also promoter
regulatory proteins of MYC (Supplementary Table 3)36. We
identiﬁed two heterogeneous nuclear ribonucleoproteins, hnRNP
A1 and hnRNP K (Fig. 3a). Co-expression of AURKA and
hnRNP K signiﬁcantly increased MYC promoter activities
compared with either alone, whereas co-expression of AURKA
and hnRNP A1 did not show similar result (Supplementary
Fig. 3a–d). As expected, there was no signiﬁcant difference in the
activation of the MYC promoter between KA and KD forms of
AURKA (Supplementary Fig. 3e–g). We thus chose hnRNP K for
further studies.
The interaction between AURKA and hnRNP K was validated
via co-immunoprecipitation (co-IP) of ectopically expressed
(Supplementary Fig. 3h,i) and endogenous (Supplementary
Fig. 3j) proteins. This binding was not affected by mutation of
S379 site in hnRNP K38 (Supplementary Fig. 3k). We further
performed glutathione S-transferase (GST) pull-down assays with
truncated forms of both proteins (Supplementary Fig. 3l,m).
Results showed that hnRNP K KI domain interacts with AURKA
283–333 domain (Supplementary Fig. 3n,o). Moreover, molecular
dynamics simulation revealed 35 combinations shown high
interaction possibilities between AURKA and hnRNP K.
Notably, the amino acids within AURKA 283–333 region
accounted for 74.3% of these combinations (Fig. 3b). The
amino acids responsible for the AURKA and hnRNP K
interaction (red colour) displayed spatial proximity (Fig. 3c).
We next examined the location where AURKA and hnRNP K
interact with each other. Although AURKA and hnRNP K were
expressed in both the cytoplasm and the nucleus, their interaction
was observed predominantly in the nucleus (Fig. 3d). The
interaction between AURKA and hnRNP K in the nucleus was
Figure 2 | Nuclear AURKA activates MYC transcription and induces a shift in MYC promoter usage. (a) DBD/AURKA-DBD, DBD-reporter and
pRL-TK were co-transfected into 293T for 24 h. Immunoblotting (IB; left panel) and dual-luciferase reporter (right panel) analysis were performed.
(b) DBD/AURKA-DBD, DBD-reporter and pRL-TK were co-transfected into 293T cells. After 12 h, cells were treated with VX-680, MLN8237 or Aurora-A
inhibitor I for 12 h. IB (left panel) and dual-luciferase reporter assay (right panel) were performed. (c) Diagram showing potential TADs in AURKA.
(d) DBD/AURKA-DBD, DBD-reporter and pRL-TK were co-transfected into 293T cells for 24 h. IB (left panel) and dual-luciferase reporter assay
(right panel) were performed. (e) STRING analysis showing connections among AURKA-regulated genes. (f) ER/AER, MYC promoter/basic reporter
and pRL-TK were co-transfected into MDA-MB-231 cells. After 6 h, AURKA nuclear translocation was induced by treating cells with 200nM OHT for 18 h.
Dual-luciferase reporter assay was performed. (g) Treatment was the same as in f. Expression of indicated genes was determined via real-time PCR and IB
analysis. (h) Treatment was similar to d, except for using MYC promoter reporter instead of DBD reporter. IB (left panel) and a dual-luciferase reporter
(right panel) analysis were performed. (i) AURKA or empty vector was co-transfected into MDA-MB-231 cells with truncated MYC promoter (MYC) or
basic reporter (Vec) along with pRL-TK. After 24 h, dual-luciferase reporter assays were performed. (j) MDA-MB-231 cells were subjected for ChIP analysis
of MYC promoter occupancy. Results were normalized with the input. (k) VX-680-treated MDA-MB-231 cells (48 h) were subjected for ChIP analysis of
MYC promoter occupancy. (l) Cells were cultured in suspended or adherent condition with same medium for 7 days. S1 nuclease protection assay (SNPA)
was performed to examine MYC P1 and P2 transcripts. Control gene, b-2-microglobulin (B2M), mRNA in parallel identical samples were also determined.
(m) BCSC and non-BCSC populations were isolated according to CD24 expression. SNPA was performed. (n) ER/AER plasmids were transfected into 293T
cells. After 6 h, AURKA nuclear translocation was induced by treating cells with 200nM OHT for 18 h. SNPA was performed. (o) DBD/AURKA-DBD were
transfected into 293T cells for 24 h. SNPA was performed. Bars represent the means±s.e.m. of three independent experiments (analysis of variance
(ANOVA) followed by least signiﬁcant difference (LSD) test; *Po0.05, **Po0.01, ***Po0.001).
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further supported by ﬂuorescence resonance energy transfer
(FRET) assay (Fig. 3e). hnRNP K contains two nuclear
localization signals (NLSs), amino acids 21–37 and amino acids
323–361 (ref. 39). We next examined whether deletion of these
two NLS might affect its interaction with AURKA. Deletion of
two NLS (labelled as Del-NLS) partially relocated hnRNP K to the
cytoplasm (Supplementary Fig. 3p), indicating that other way
might allow hnRNP K to enter the nucleus in addition to these
speciﬁc NLSs. Co-IP showed that deletion of two NLSs weakened
the interaction between AURKA and hnRNP K (Fig. 3f). We also
extracted the cytoplasmic and nuclear lysates from cells over-
expressing the WT hnRNP K or Del-NLS mutant for co-IP
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Figure 3 | AURKA and hnRNP K efﬁciently interacts in the nucleus. (a) AURKA-interacting proteins were identiﬁed using SILAC assay (red area).
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staining of AURKA. Scale bar, 100mm. (j) The lysates of samples 1–3 were subjected to IB using antibodies as indicated. (k) The lysates of samples 1–3 were
subjected to IP and IB using antibodies as indicated. Bars represent the means±s.e.m. of three independent experiments (analysis of variance (ANOVA)
followed by least signiﬁcant difference (LSD) test; *Po0.05, **Po0.01, ***Po0.001).
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Figure 4 | hnRNP K is required for AURKA to activate MYC transcription and enhance BCSC phenotype. (a) Chromatin from MDA-MB-231 cells was
extracted for ChIP and re-ChIP analysis. Results were normalized by input. (b) MDA-MB-231 cells were transfected with siRNA against negative control
(NC), AURKA or hnRNP K for 48 h. ChIP assays were performed. (c) MDA-MB-231 cells overexpressing HA-tagged AURKA were transfected with hnRNP
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MYC promoter ( 226/þ 211) (upper panel). Lower panel shows probes used for SNPA. ‘CT’ represented CT element. The mutant chimeric gene was
mutated at hnRNP K-binding site. (g) Chimeric gene or its mutant were co-transfected with AURKA and pRL-TK plasmids into 293T cells for 24 h. SNPA
was performed using the probes shown in f. In parallel, a fraction of these cells was evaluated for Renilla luciferase activity, which reﬂects the transfection
efﬁciency. (h,i,j) 293T cells were transfected with hnRNP K siRNA for 24 h. Cells were then co-transfected with WTor NLS-deleted hnRNP K, AURKA and
MYC promoter or basic reporter along with pRL-TK for another 24 h. Transfected cells were harvested for immunoblotting (IB) (h), dual-luciferase reporter
(i) and real-time PCR (j) analysis. (k) MCF-10A cells overexpressing HA-AURKA were transfected with hnRNP K or NC siRNA. After 48 h, cells were
collected to analyse CD24/CD44. (l) hnRNP K was knocked down in AURKA-overexpressing or control 10A-K-Ras (G12V) cells. Cells were sorted
according to CD24 expression. CD24Low population was used to perform limiting dilution assays. Bar represented the means±s.e.m. of three independent
experiments (analysis of variance (ANOVA) followed by least signiﬁcant difference (LSD) test; *Po0.05, **Po0.01, ***Po0.001).
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studies. Both the WT hnRNP K and Del-NLS mutant interacted
efﬁciently with AURKA in the nucleus (Fig. 3g), whereas their
interactions with AURKA were very weak in the cytoplasm. We
also examined the cytoplasmic and nuclear proteins extracted
from AER-overexpressing cells, which were treated or untreated
with OHT. Similarly, AURKA and hnRNP K showed higher
interaction efﬁciencies in the nuclear fraction compared with that
in the cytoplasmic fraction (Fig. 3h). Furthermore, we performed
co-IP using breast cancer tissues, which displayed different levels
of nuclear/cytoplasmic AURKA expression. Sample 1 displayed
strong nuclear AURKA staining, sample 2 showed strong
cytoplasmic AURKA staining and sample 3 showed low nuclear
AURKA staining (Fig. 3i,j). The interaction between AURKA and
hnRNP K is strong when AURKA is predominantly expressed in
the nucleus (Fig. 3k lower panel, compare lane 2 with 6), but the
interaction is weak when AURKA is predominantly expressed in
the cytoplasm (Fig. 3k lower panel, compare lanes 2 and 6 with
lane 4). These data suggest that AURKA and hnRNP K
preferentially interact in the nucleus.
hnRNP K is required for AURKA to activateMYC transcription.
We used re-ChIP assays to determine whether AURKA and
hnRNP K co-occupy the same region of the MYC promoter. We
found that AURKA formed a complex with hnRNP K on the
MYC promoter (Fig. 4a). Further, ChIP assays were performed
following depletion of AURKA or hnRNP K by siRNA. AURKA
depletion failed to abolish the binding of hnRNP K to the MYC
promoter (Supplementary Fig. 4a and Fig. 4b), whereas hnRNP K
silencing abolished AURKA binding. These results suggest that
the binding of AURKA to theMYC promoter depends on hnRNP
K. In addition, depletion of hnRNP K by siRNA also abolished
the ability of AURKA to upregulate the expression of MYC
(Fig. 4c and Supplementary Fig. 4b,c) in MDA-MB-231 cells. We
further mutated the hnRNP K-binding sites in theMYC promoter
(Supplementary Fig. 4d) and found that the mutant promoter was
no longer activated in response to AURKA and/or hnRNP K
overexpression (Fig. 4d and Supplementary Fig. 4e). Consistently,
downregulation of hnRNP K or mutation of the hnRNP
K-binding sites in the MYC promoter abolished the AURKA
promoted utilization of MYC P1 (Fig. 4e–g). We also examined
whether NLS-deleted hnRNP K rescues the MYC expression.
NLS-deleted hnRNP K was less effective in rescuing the MYC
expression than the WT hnRNP K (Fig. 4h–j). Moreover,
phosphorylation-mimicking (S379D) and non-phosphorylatable
(S379A) mutants of hnRNP K activated the MYC promoter at
similar levels (Supplementary Fig. 4f), suggesting that phos-
phorylation of hnRNP K at Ser379 by AURKA is not required for
activating MYC promoter.
hnRNP K is required for AURKA to enhance BCSC phenotype.
We next evaluated whether nuclear AURKA-enhanced BCSC
phenotype was mediated by hnRNP K. Depletion of hnRNP K by
siRNA suppressed the CD24low/CD44high population to the same
extent observed in MCF-10A and SUM149 cells in the presence
or the absence of AURKA overexpression (Fig. 4k and
Supplementary Fig. 4g). We therefore propose that the ability of
AURKA to promote BCSC population depends on hnRNP K.
To validate this, we expressed c-Myc at physiological levels
from an exogenous WT or mutated MYC promoter (Mut CT)
and then monitored mammosphere formation in these cells.
A slightly increased expression of c-Myc (Supplementary Fig. 4h,
comparing lanes 4 and 7 with lane 1) indicated that exogenous
AURKA and hnRNP K were expressed at physiological levels.
MDA-MB-231 cells harbouring exogenous WT, but not mutant,
MYC promoter expressed higher levels of c-Myc when AURKA
or/and hnRNP K were also expressed (Supplementary Fig. 4h,
comparing lane 5 with 4, lane 8 with 7 and lane 11 with 10). The
size and the number of spheres also indicated that only cells
harbouring WT MYC promoter showed enhanced sphere
formation in response to the expression of exogenous AURKA
or/and hnRNP K (Supplementary Fig. 4i). Cells used in
mammosphere formation assays were then subjected to adherent
culture. These cells displayed similar proliferation kinetics
(Supplementary Fig. 4j), indicating that the above-mentioned
effects were probably linked to self-renewal.
Limiting dilution assays were performed in nonobese diabetic/
severe combined immunodeﬁcient mice, to analyse the potential
role of hnRNP K in regulating nuclear AURKA-promoted BCSC
property. The tumorigenicity of cells overexpressing AURKA was
examined in the context of hnRNP K downregulation. The
CD24High population failed to generate tumours over a 3-month
period with injection of o1 105 cells (Supplementary Fig. 4k).
In contrast, tumour growth was observed in the CD24Low
population when cell number was o1 105 and became more
apparent when AURKA was overexpressed (Fig. 4l), suggesting
that AURKA plays a role in tumour initiation. The effect of
AURKA on promoting tumour initiation was abolished by
knocking down hnRNP K (Fig. 4l), further supporting the role of
hnRNP K in AURKA-mediated BCSC property. The CD24Low
cells were isolated and subjected to adherent culture, to evaluate
their proliferation potential. Overexpression of AURKA margin-
ally increased proliferation rate relative to vector control, whereas
downregulation of hnRNP K abolished the growth-promoting
effects of AURKA and slightly decreased the proliferation relative
to the vector control (Supplementary Fig. 4l). These results
indicate that the dramatic reduction in tumorigenicity induced
by knocking down hnRNP K was not caused by the mild
Figure 5 | AURKA nuclear localization sequence is required to enhance breast cancer stem cell phenotype. (a) Enhanced green ﬂuorescent protein
(EGFP)-fused truncated forms of AURKA were transfected into 293T cells for 24 h. The localization of EGFP-fused truncated forms of AURKA were
analysed via confocal microscopy. Scale bar, 25mm. (b) DsRed-fused 333–383 region of AURKA was transfected into 293Tcells for 24 h. The localization of
DsRed-fused 333–383 region of AURKA was analysed by confocal microscopy. Scale bar, 25mm. (c,d) MDA-MB-231 cells were co-infected with lentivirus
expressing AURKA shRNA (shAURKA/sh Control) and the truncated protein (1–383 or 1–333). Puromycin (1mgml 1) and blasticidin (5 mgml 1) selected
cells were subjected to immunoblotting (IB) analysis (c) or CD24low/CD44high population analysis via ﬂow cytometry (d). (e) The cells in c were subjected
to mammospheres culture assay for 6 days. The left panel shows the distribution pattern according to mammosphere size (Kruskal–Wallis test followed by
Dunn’s multiple comparison test, ***Po0.001). The right panel showed the number of F460mm mammospheres. (f) AURKA (1–333) was fused with ER
via a nuclear localization sequence to generate ER-NLS-AUR333 fusion protein (upper panel). MDA-MB-231 cells were co-infected with lentivirus
expressing AURKA shRNA (shAURKA/sh Control) and the fusion protein (ER-NLS-AUR333). The cells were then cultured in fresh medium for 48 h in the
presence or absence of 200nM OHT. Puromycin (1mgml 1) and blasticidin (5mgml 1) selected cells were harvested for CD24/CD44 staining and
analysis via ﬂow cytometry (lower panel). (g) The cells in f were cultured in mammosphere medium with or without 200 nM OHT. The cells were then
photographed and quantiﬁed at the end of the ﬁrst-round mammosphere culture (6 days) and the secondary passaging (additional 6 days). The left panel
shows the distribution pattern of mammosphere size from MDA-MB-231 (Kruskal–Wallis test followed by Dunn’s multiple comparison test, ***Po0.001).
The right panel shows the number of mammosphere (F460mm). Data were presented as the means±s.e.m. of three independent experiments (analysis
of variance (ANOVA) followed by least signiﬁcant difference (LSD) test; *Po0.05; **Po0.01; ***Po0.001).
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proliferation attenuation that we observed in the adherent
culture.
AURKA NLS is required to enhance BCSC phenotype. We also
asked whether AURKA contains an NLS. We found that deletion
of the amino acids 333–383 in AURKA blocked its nuclear
localization (Fig. 5a and Supplementary Fig. 5a), indicating that
this region contains NLS. These data also suggest that the NES of
AURKA may reside in amino acids 1–333. We fused the putative
NLS (amino acids 333–383 amino acid) to DsRed. Cells
expressing DsRed alone demonstrated a nearly homogeneous
distribution in 293T cells (Fig. 5b left panel), whereas
DsRed-333–383 fusion protein was partially induced to localize to
the nucleus (Fig. 5b right panel), indicating that this region
of AURKA possesses nuclear localizing function. hnRNP K
overexpression, inhibition of AURKA kinase activity or deletion
of NLS of hnRNP K did not signiﬁcantly affect the subcellular
distribution of AURKA (Supplementary Fig. 5b–d).
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Truncated forms of AURKA (1–383 and 1–333) were used to
perform rescue assay, to examine the role of nuclear AURKA in
regulating BCSC phenotype. Although both the 1–383 and
1–333 regions rescued the proliferation in adherent culture
(Supplementary Fig. 5e), only 1–383 regions of AURKA rescued
BCSC phenotype (Fig. 5c–e). To conﬁrm this, amino acids 1–333
of AURKA were fused with ER via the SV40 T-antigen NLS, to
generate fusion protein labelled as ER-NLS-AUR333 (Fig. 5f
upper panel). In the absence of OHT, ER-NLS-AUR333
predominantly localized to the cytoplasm. However, following
incubation with OHT, a fraction of ER-NLS-AUR333 proteins
translocated to the nucleus (Supplementary Fig. 5f). We then
investigated whether ER-NLS-AUR333 would reconstitute
BCSC expansion following endogenous AURKA depletion by
short hairpin RNA (shRNA; Supplementary Fig. 5g). Only
nuclear-localized ER-NLS-AUR333 rescued the CD24low/
CD44high population (Fig. 5f lower panel and Supplementary
Fig. 5h) and the ability to form spheres following depletion of
endogenous AURKA (Fig. 5g). Furthermore, we found that the
ability to form spheroids in secondary passage was retained only
when the ER-NLS-AUR333 was expressed in the nucleus
(Fig. 5g). The proliferation of the cells used to perform
mammosphere culture could be rescued by ER-NLS-AUR333 in
adherent culture regardless of its cellular localization, indicating
that the above-mentioned effects were more probably linked to
self-renewal (Supplementary Fig. 5i).
Reducing nuclear AURKA sensitizes AKI-resistant BCSC.
Endogenous AURKA was downregulated by shRNA (expressing
red ﬂuorescent protein (RFP)) in AER-expressing MDA-MB-231
cells. The resulting RFP-positive cells separated by ﬂuorescence-
activated cell sorting (FACS) were subjected to immunoblotting
analysis (Fig. 6a red rectangle) and assayed for their ability
to establish tumours in nude mice. Blocking AURKA nuclear
localization (in the absence of OHT, group 2) attenuated tumour
growth in xenograft model (Fig. 6b). Results from these
experiments also established that the combination of AURKA
inhibition (VX-680) and blocking AURKA nuclear localization
had an additive tumour growth suppression effect (Fig. 6b,
group 4). IHC staining of subcutaneous tumour sections con-
ﬁrmed that OHT regulated the subcellular localization of AURKA
(Fig. 6c upper panel; image 2/4 compared with image 1/3),
and that VX-680 suppressed AURKA phosphorylation at T288
(Fig. 6c lower panel; image 3/4 compared with image 1/2).
Next, we analysed the BCSC phenotype of cells isolated from
the xenografts. The CD24low/CD44high population was somewhat
decreased when either the kinase activity or nuclear translocation
of AURKA was blocked and even more substantially when both
were inhibited (Fig. 6d). Sphere-formation assays also revealed
similar synergetic anti-BCSC effects (ﬁrst and second) when both
AURKA kinase activity and nuclear translocation were blocked
(Fig. 6e,f). These cells also displayed similar proliferative potential
in adherent culture (Supplementary Fig. 6a), indicating that the
effects observed in mammosphere culture were more likely to be
speciﬁcally linked to self-renewal.
We further evaluated the effects of Aurora kinase inhibition on
the oncogenic function of nuclear or cytoplasmic AURKA.
Immunoﬂuorescent staining showed that NES- and NLS-fused
AURKA localized to the cytoplasm and the nucleus, respectively
(Supplementary Fig. 6b). The kinase activity of these
fusion proteins could be effectively inhibited by MLN8237
(Supplementary Fig. 6c). AURKA kinase inhibitor signiﬁcantly
suppressed the CD24low/CD44high population in cells expressing
AURKA-NES (Supplementary Fig. 6d,e) but not in cells
expressing AURKA-NLS (Supplementary Fig. 6d,e). These results
suggest that the oncogenic function of cytoplasmic AURKA relies
predominantly on its kinase function, and that nuclear AURKA
possesses kinase-independent activity, which is not repressed by
the AURKA kinase inhibitor.
Clinical relevance of nuclear AURKA expression. To further
substantiate the positive regulatory role of nuclear AURKA and
hnRNP K in MYC expression and promotion of BCSC pheno-
type, we isolated primary cells from human breast cancer tissues.
The purity of the enriched epithelial cells from these tissues was
485% in ten samples (Supplementary Fig. 7a). A correlation
analysis was performed for the expression of nuclear/cytoplasmic
AURKA, c-Myc, hnRNP K (Fig. 7a) and the ratio of the CD24low/
CD44high population (Fig. 7b). Nuclear but not cytoplasmic
AURKA expression was positively correlated with the percentage
of the CD24low/CD44high population and the expression of
nuclear c-Myc (Fig. 7c). We then performed IHC staining
of AURKA, CD24, c-Myc and hnRNP K, to determine their
correlations. The cutoff values used to distinguish between high
and low expression were determined by a receiver operating
characteristic plot (Supplementary Fig. 7b–d). Nuclear AURKA
expression was positively correlated with c-Myc expression and
negatively correlated with CD24 expression (Fig. 7d). A higher
nuclear AURKA expression indicated a poorer prognosis for
patients (Supplementary Fig. 7e). Nuclear AURKAhigh/c-Mychigh
expression predicted an inferior overall survival when compared
with AURKAhigh/c-Myclow, AURKAlow/c-Mychigh or AURKAlow/
c-Myclow expression (Fig. 7e). MYC is frequently ampliﬁed in
various cancers40. To conﬁrm the correlation between AURKA
and MYC, we re-evaluated their correlations in samples with
normal MYC copy number. We found that 53 of 59 samples
showed normal MYC copy number. We then subjected these
samples to IHC staining of AURKA and c-Myc, and studied 31
samples with both of IHC staining of AURKA and c-Myc.
Nuclear AURKA expression was still positively correlated with
c-Myc expression (Supplementary Fig. 7f). In summary, these
clinical data support our ﬁndings that nuclear AURKA is
important for the regulation of MYC expression and thus the
oncogenic properties of BCSC.
Discussion
AURKA is known for its function in cell cycle, where it acts in the
cytoplasm during prophase of mitosis to organize the centro-
somes. Here we establish a new molecular role for AURKA by
demonstrating that nuclear AURKA promotes the expansion of
BCSC. Mechanistically, nuclear AURKA acts as a transactivating
factor to activate the expression of MYC from P1 promoter via its
interaction with hnRNP K. The activation of MYC by AURKA is
dependent on the nuclear localization of AURKA rather than its
kinase activity. We further demonstrate that amino acids 333–383
are responsible for nuclear translocation of AURKA. Finally, we
show that blocking AURKA nuclear localization sensitizes
resistant BCSCs to AURKA kinase-targeted therapy.
Transcripts initiated from two tandem promoters, P1 and P2,
account for the majority of MYC expression. In normal
proliferating cells, the ratio of P1/P2 transcripts varies between
1:10 and 1:5 (ref. 36). In some cases, the relative utilization of P1
and P2 promoter is changed, inducing a higher ratio of P1 to P2
transcripts. In Burkitt’s lymphoma, the MYC locus (8q24) is
commonly juxtaposed through chromosomal translocation to one
of the immunoglobulin loci IgH (14q32), Igk (2p12) or Igl
(22q11)41. These translocations cause P1 to be more active than
P2. In addition, the shift in MYC P1/P2 promoter utilization is
also found during the cell cycle activation of lymphocytes42 and
the postnatal cerebellar development43. Interestingly, we also
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Figure 6 | Blocking AURKA nuclear translocation enhances the anticancer effects of Aurora kinase inhibitor. (a) MDA-MB-231 cells expressing
AURKA-ER were infected with lentiviral expressing AURKA shRNA or control. The cells were sorted for RFP (þ ) and the lysates were examined via
immunoblotting (IB). (b) MDA-MB-231 cells sorted from a (red rectangle) were inoculated subcutaneously in nude mice. Mice treated with OHTwere then
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See also Supplementary Methods. (c) IHC staining was performed on tumours harvested at the end of the animal experiment (b). Scale bar, 100 mm.
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found that the shift in MYC P1/P2 promoter utilization also
occurs in BCSC (Fig. 2l and Supplementary Fig. 2n), suggesting
that the relative utilization ofMYC P1 and P2 could be a hallmark
for BCSC. Our data indicate that AURKA binds to MYC
promoter to induce a shift in MYC P1/P2 promoter utilization
(Fig. 2j,n). The CT element locates at 100–150 bp 50 of the P1
promoter and contains ﬁve, in part, imperfect repeats of the
sequence 50-CCCTCCCC-30 (refs 44,45). The integrity of CT
element is essential for P1 promoter activation and is important
for maintaining maximal P2 activity45. Various factors bind
0 50 100 150
0
50
100
150
3: AURKA (high)/Myc (high) (n=99)
2: AURKA (high)/Myc (low) (n=82)
0/1: P=0.0149
0/2: P=0.0138
0/3: P<0.0001
1/2: P=0.9148
1/3: P=0.0217
2/3: P=0.0131
1: AURKA (low)/Myc (high) (n=87)
0: AURKA (low)/Myc (low) (n=220)
Month
O
ve
ra
ll s
ur
viv
al
 (%
)
CD24
CD
44
Patient 1 Patient 2 Patient 3 Patient 4
7.8% 13.4% 16.0% 2.6%
Patient 5 Patient 6 Patient 7 Patient 8
3.8% 18.4% 17.0% 25.3%
Patient 9 Patient 10
1.4% 10.3%
d
e
c-MycCD24AURKA c-MycCD24AURKA
Nuclear AURKA low
f
0 2 4 6
0
10
20
30
40 CD24
r 2=0.7368
P=0.0015
c-Myc (nuclear)
r 2=0.8469
P=0.002
hnRNP K (nuclear)
r 2=0.2162
P=0.1758
CD24
r 2=0.0002
P=0.9707
c-Myc (nuclear)
r 2=0.1450
P=0.2776
hnRNP K (nuclear)
r 2=0.0812
P=0.4250
Normalized nuclear AURKA expression
CD
24
Lo
w
/C
D4
4H
ig
h (%
)
o
r 
n
o
rm
a
liz
ed
 c
-M
yc
 e
xp
re
ss
io
n
o
r 
n
o
rm
a
liz
ed
 h
nR
NP
 K
 e
xp
re
ss
io
n
CD
24
Lo
w
/C
D4
4H
ig
h (%
)
o
r 
n
o
rm
a
liz
ed
 c
-M
yc
 e
xp
re
ss
io
n
o
r 
n
o
rm
a
liz
ed
 h
nR
NP
 K
 e
xp
re
ss
io
n
0.0 0.5 1.0 1.5 2.0 2.5
0
10
20
30
40
Normalized cytopalsmic AURKA expression
55 kDa
55 kDa
55 kDa
40 kDa
25 kDa
Nuclear AURKA high
Pa
tie
nt 
1
Pa
tie
nt 
2
Pa
tie
nt 
3
Pa
tie
nt 
4
Pa
tie
nt 
5
Pa
tie
nt 
6
Pa
tie
nt 
7
Pa
tie
nt 
8
Pa
tie
nt 
9
Pa
tie
nt 
10
Cy
to
N
uc
l
Cy
to
N
uc
l
Cy
to
N
uc
l
Cy
to
N
uc
l
Cy
to
N
uc
l
Cy
to
N
uc
l
Cy
to
N
uc
l
Cy
to
N
uc
l
Cy
to
N
uc
l
Cy
to
N
uc
l
AURKA
hnRNP K
Histone H3
c-Myc
β-actin
103
103
102
102
101
101
100
100
103
102
101
100
103
102
101
100
103
102
101
100
103
102
101
100
103102101100
103
102
101
100
103102101100
103
102
101
100
103102101100
103102101100
103
102
101
100
103102101100
103
102
101
100
103102101100
103102101100 103102101100
103
102
101
100
103102101100
C1
C3 C4
F3 C3 C3C4
C3 C4 C3 C4
C4 C4C3F4
F1 C1 C1C2
C1 C2 C1 C2
C2 C1 C2
3.8%
1.4%
0.0% 0.1% 23.1%80.3%
10.3% 66.8%18.5%
18.4% 17.0% 25.3% 3.2%14.2%46.1%
4.0% 2.3% 42.3% 5.3% 66.5%33.4% 26.9%77.7%
14.8%
F2
C3 C3C4 C4 C3 C4
C2 C1 C1C2 C2 C1 C2
7.8% 13.4% 16.0% 2.6% 8.2%41.7%2.6%
14.1% 60.7% 1.9% 20.8% 68.5%23.6% 40.7%
44.9%
33.2%
c-Myc
H-score154
H-score156
H-score >154
H-score >156
Total
H-score171 H-score >171
Total
Total
AURKA H-score156H-score >156
Total
AURKA22083
303
87
98
185
307
181
488
P <0.001 P <0.001
CD24
93
117
210
215
58
273
308
175
483
Normal breast cells Breast cancer cells Breast cancer cells Breast cancer cells
Cytoplasm Cytoplasm Cytoplasm Cytoplasm
MYC promoter
Nucleus
MYC promoter
Nucleus
MYC promoter
Nucleus
MYC promoter
Nucleus
ANLIAKI
Stem cell
fate determination
Inactivated form of AURKA
Activated form of AURKA
hnRNP K
MYC mRNA
Cancer stem cells
AKI: aurora kinase inhibitor
ANLI: AURKA nuclear location inhibitor
a b
c
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10180
12 NATURE COMMUNICATIONS | 7:10180 | DOI: 10.1038/ncomms10180 | www.nature.com/naturecommunications
speciﬁcally to CT element, to modulate MYC promoter activity.
For example, Sp1 binds to the duplex form45, hnRNP K to C-rich
single strands44 and CNBP to G-rich single strands46. Our data
show that mutation of CT element abolished AURKA-induced P1
promoter activation (Fig. 4d,g). Consistently, downregulation of
hnRNP K suppressed the interaction between AURKA and CT
element, and abolished the AURKA-induced shift in MYC P1/P2
promoter utilization (Fig. 4b,e).
Although we show that AURKA promotes MYC expression by
acting as a transactivating factor in a kinase-independent manner,
there are multiple routes through which AURKA could activate
MYC expression. AURKA may interact with the WNT/b–catenin
pathway. Overexpression of AURKA increases the phosphoryla-
tion of GSK-3b at Ser 9 and the nuclear b-catenin levels, which
enhances b-catenin/TCF transcription activity and the transcrip-
tion of its downstream target genes including CCND1 and
MYC47. p53 controls the expression of multiple cell cycle genes
such as MYC48. AURKA may also regulate cell cycle activation or
MYC expression by modulating p53 function31. Our previous
study showed that inhibition of AURKA kinase activity by
AKI603 induced the downregulation of c-Myc protein level49. We
considered that the downregulation of c-Myc by Aurora kinase
inhibitor is caused by the secondary effects of growth arrest. To
exclude the impact of growth arrest, we conducted kinase activity
inhibition in cells synchronized in M phase, to evaluate c-Myc
expression. Our data showed that the expression of c-Myc is not
reduced by Aurora kinase inhibitor VX-680 in synchronized cells,
whereas the expression of c-Myc was reduced in unsynchronized
cells after VX-680 treatment (Supplementary Fig. 7g).
AURKA is critical for mitosis because of its role in regulating
centrosome function50 and microtubule dynamics51. This
AURKA function is probably dependent on its cytoplasmic
activity due to the cytoplasmic localization of its substrates in the
centrosome and microtubule. Recent studies show that mitotic
function of AURKA is critical for regulating stem cell function.
AURKA participates in the control of cell fate determination
through modulating the asymmetric distribution of cell fate
determinant52 and the orientation of the mitotic spindle53.
Consistent with previous study49, our data show that inhibition of
AURKA kinase activity reduces the BCSC population (Fig. 6d).
The suppression of BCSC through inhibition of AURKA kinase
activity might be mainly due to impairing the function of
cytoplasmic AURKA. Accordingly, we found that inhibition of
AURKA kinase activity greatly reduced the CD24low/CD44high
BCSC population in cells expressing NES-fused AURKA, but not
in cells expressing NLS-fused AURKA (Supplementary Fig. 6d,e).
These results suggest that the oncogenic function of cytoplasmic
AURKA relies predominantly on its kinase function, and that
nuclear AURKA possesses kinase-independent activity, which is
not repressed by the AURKA kinase inhibitor.
Although inhibiting the kinase activity of AURKA induced
anti-BCSC effects, a signiﬁcant proportion of BCSC is refractory
to the kinase activity inhibition (Fig. 6d). Targeting the
transactivating function by preventing AURKA translocation to
the nucleus signiﬁcantly enhanced the ability of AURKA kinase
to inhibit the expansion of BCSC (Fig. 6e,f). Previous studies have
identiﬁed several mutations of AURKA in cancer, such as F31I
and V57I54. Interestingly, the low-kinase-activity AURKA mutant
(F31/I57) can induce higher levels of genomic instability and
increase oesophageal cancer risk compared with other kinase-
dependent mutations such as (I31/V57)54. These ﬁndings are
consistent with our results that indicated AURKA may promote
cancer development via mechanisms that are independent of its
kinase activity. In addition, other studies have indicated that
AURKA stabilizes N-Myc independently of its kinase activity17,
and that N-Myc can be destabilized using the Aurora kinase
inhibitor, MLN8237, which disrupts the interaction between
N-Myc and AURKA55. Although these previous studies suggest a
strategy to overcome drug resistance to kinase-activity inhibition
by disrupting protein–protein interactions, our new ﬁndings
strongly support an alternative therapeutic avenue by blocking
the nuclear localization of AURKA.
In summary, our study demonstrates that the spatial
deregulation of AURKA confers a previously unknown oncogenic
function to AURKA that is not sensitive to conventional
kinase inhibitory strategies and contributes to drug resistance.
These new ﬁndings further advance our understanding of the
mechanism of drug insensitivity and provide a novel strategy to
overcome drug resistance (Fig. 7f).
Methods
Chemicals and antibodies. VX-680, MLN8237 and Aurora A Inhibitor I were
purchased from Selleck Chemicals. OHT, Nocodazole and puromycin were pur-
chased from Sigma-Aldrich. The following primary antibodies were used: AURKA
(rabbit; Millipore, 1:4,000, catalogue number 07–648), AURKA (mouse; Abcam,
1:4,000, catalogue number ab13824), phospho-AURKA (T288; Cell Signaling,
1:1,000, catalogue number 3079), haemagglutinin (HA) tag (Sigma-Aldrich,
1:4,000, catalogue number SAB4300603), FLAG tag (Sigma-Aldrich, 1:4,000,
catalogue number F1804), glyceraldehyde 3-phosphate dehydrogense (Thermo
Fisher Scientiﬁc, 1:4,000, catalogue number AM4300), b-actin (Cell Signaling,
1:4,000, catalogue number 4967), c-Myc (Santa Cruz, 1:2,000, catalogue number
sc-764), Histone H3 (Cell Signaling, 1:2,000, catalogue number 4499), hnRNP K
(Cell Signaling, 1:4,000, catalogue number 4675), enhanced green ﬂuorescent
protein (Cell Signaling, 1:4,000, catalogue number 2555), GST (Cell Signaling,
1:4,000, catalogue number 2624s), Erk1/2 (Cell Signaling, 1:2,000, catalogue
number 9102), phospho-Erk1/2 (Thr202/Tyr204; Cell Signaling, 1:2,000, catalogue
number 9101), Ras (Cell Signaling, 1:1,000, catalogue number 3965), phospho-p53
(Ser315; Cell Signaling, 1:1,000, catalogue number 2528), p53 (Cell Signaling,
1:1,000, catalogue number 2524s), phospho-Histone H3 (Ser10; Cell Signaling,
1:1,000, catalogue number 9701), Histone H3 (Cell Signaling, 1:1,000, catalogue
number 9715).
Cell lines. Human breast cancer cell lines (BT549, MDA-MB-231, MCF-10A and
Sk-br-3), mouse embryonic ﬁbroblasts and 293T cells were obtained from the
Figure 7 | Clinical relevance of nuclear AURKA expression. (a,b and c) Primary breast cancer cells were isolated from breast cancer tissues derived from
ten patients. Nuclear and cytoplasmic fractions were subjected to immunoblotting (IB) analysis (a). The expression of CD24 and CD44 were analysed
using ﬂow cytometry (b). Nuclear and cytoplasmic fractions of AURKA were normalized using histone H3 and b-actin, respectively. The nuclear fraction of
c-Myc and hnRNP K were normalized using histone H3. The normalized AURKA, c-Myc, hnRNP K and the CD24low/CD44high population derived from the
same patient were used to compose a scatterplot and linear regression analysis performed (c). (d) Breast cancer tissues were subjected to IHC staining for
indicated antibodies. Representative images were acquired with  10 and 40 objectives (upper panel). Scale bar, 50mm. Pearson’s w2-test was used to
analyse the correlation between nuclear AURKA and c-Myc/CD24 (lower panel). (e) IHC staining for AURKA and c-Myc was performed on breast cancer
tissues. Kaplan–Meier analysis was performed and log-rank test used to make statistical comparisons. (f) During breast cancer development, AURKA is
overexpressed and translocates to the nucleus, where the nuclear AURKA acts as a transactivating factor that binds and activates the MYC promoter
through its interaction with hnRNP K. Through these mechanisms, nuclear AURKA enhances BCSC phenotype. Importantly, these processes are dependent
on the nuclear localization of AURKA rather than its kinase activity. Traditional targeted therapies focus on the inhibition of kinase activity, which may be
insufﬁcient for suppressing the kinase-independent oncogenic actions. These new ﬁndings suggest that targeting the spatial deregulation of kinase could be
a promising strategy for overcoming kinase inhibitor insensitivity.
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American Type Culture Collection (ATCC). These cell lines were authenticated
at ATCC before purchase by their standard short tandem repeat DNA-typing
methodology. SUM149 was kindly provided by Professor Zhimin Shao
(Department of Medical Oncology, Cancer Hospital of Fudan University, Shanghai
Medical College, China). SUM149 was authenticated by the standard short tandem
repeat DNA-typing methodology. Each cell line was cultured in its standard
medium as recommended by ATCC. The SUM149 cells were cultured in F12
(Gibco) supplemented with 5% fetal bovine serum (Hyclone), 5 mgml 1 insulin
(Sigma-Aldrich) and 1 mgml 1 hydrocortisone (Sigma-Aldrich). All cells were
maintained at 37 C in a humidiﬁed 5% CO2 atmosphere.
Human breast cancer specimens and primary cell isolation. Following
informed consent and in accordance with the guidelines of the Institutional Review
Boards, breast cancer specimens were obtained from patients undergoing surgery at
the Third Afﬁliated Hospital of Sun Yat-Sen University, China. Primary breast
cancer isolation was performed. Ten breast lesions, following histological
diagnostic assessment and sampling by pathologists, were mechanically and
enzymatically dissociated to yield clumps of epithelial cells, termed organoids,
by incubating at 37 C for 2 h in a 1:1 solution of collagenase I (3mgml 1)/
hyaluronidase (100Uml 1) (Sigma-Aldrich). After ﬁltration through a 40-mm
pore ﬁlter and washing with PBS, the organoids from tumour tissues were
dissociated into single cells using trypsin, for subsequent cytoplasmic and nuclear
protein isolation and CD24/CD44 analysis.
RNA interference. The target sequences of AURKA siRNAs (GenePharma) were
as follows: 1, 50-ATGCCCTGTCTTACTGTCA-30 ; 2, 50-GGCAACCAGTGTACCT
CAT-30 ; and 3, 50-ATTCTTCCCAGCGCGTTCC-30 . The target sequence of
hnRNP K siRNA (GenePharma) was 50-AATATTAAGGCTCTCCGTACA-30 and
the negative control siRNA sequence was 50-TTCTCCGAACGTGTCACGT-30 .
The shAURKA (TRC number: TRCN0000000655) and sh control (SHC002)
plasmids were purchased from Sigma-Aldrich. The shRNA sequences against
hnRNP K (sense: 50-CGCGTCCCCGTTATTGTTGGTGGTTTAATTCAAGAGA
TTAAACCACCAACAATAACTTTTTGGAAAT-30 and antisense: 50-CGATTT
CCAAAAAGTTATTGTTGGTGGTTTAATCTCTTGAATTAAACCACCAACAA
TAACGGGGA-30) were cloned into pLVTHM (Addgene).
Immunoprecipitation. The cells were lysed in RIPA buffer containing 50mM Tris
pH 7.4, 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1mM
phenylmethyl sulfonyl ﬂuoride, complete protease and phosphatase inhibitor
cocktail (Roche). Co-IP was performed by using 1 mg of antibodies and 200–500 mg
of lysate for exogenous proteins or 2–5mg of lysate for endogenous proteins.
Clean-Blot IP Detection Reagents (Thermo Scientiﬁc) were used to recognize the
native primary antibody.
GST pull-down assays. 293T cells overexpressing HA-tagged AURKA or hnRNP
K were lysed in RIPA buffer. Equal amounts (5mg) of the GST fusion proteins were
incubated in the lysate for 1 h at 4 C. Glutathione–agarose beads (Sigma-Aldrich)
were incubated in the lysate for 1 h at 4 C. Next, the beads were washed three
times with lysis buffer and eluted by boiling in SDS sample buffer.
Immunoblotting. Cells were washed twice with cold PBS. Next, cells were lysed in
RIPA buffer containing 50mM Tris pH 7.4, 150mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS, 1mM phenylmethyl sulfonyl ﬂuoride, complete
protease and phosphatase inhibitor cocktail (Roche) for 5min, and were collected
by scraping. Lysates were cleared by centrifuging at 12,000 r.p.m. for 10min.
Protein was quantiﬁed by Bradford Assay. Sample proteins were separated by
SDS–PAGE gel electrophoresis. Next, proteins were transferred from gel to a
nitrocellulose membrane (Millipore). After that, membranes were blocked in 5%
BSA TBST for 30min at room temperature (RT) and then incubated overnight
with indicated primary antibodies at 4 C. After that, membranes were washed
three times and incubated with peroxidase-conjugated secondary antibodies
(1:5,000, Millipore) and detected with enhanced chemiluminescence (Millipore)
on X-ray ﬁlms (Kodak). Uncropped scans of all the blots are shown in
Supplementary Fig. 8.
Animal studies. Animal care was performed with approval of the Institutional
Animal Care and Use Committee at Sun Yat-Sen University Cancer Center.
For limiting dilution assays (Fig. 4l), cells sorted according to CD24 expression
were serially diluted from 1 105 to 1 102 cells per 100 ml in PBS containing 50%
Matrigel (BD Biosciences), followed by subcutaneous injection into nonobese
diabetic/severe combined immunodeﬁciency mice. Tumour formation was
examined once every 4 days and the total observation period was 16 weeks.
For the animal studies presented in Fig. 6b, the AER fusion gene and the
puromycin-resistance gene were expressed via lentivirus-mediated gene transfer.
Endogenous AURKA was knocked down via lentivirus delivery of shRNA
(shAURKA); RFP was also expressed by the same lentivirus vector. MDA-MB-231
cells expressing the AER fusion protein and AURKA shRNA were initially selected
using 1 mgml 1 puromycin for 48 h, followed by FACS sorting according to
the RFP signal intensity. Female nude mice (4–6 weeks of age) were injected
subcutaneously into the right ﬂank with 2 106 cells containing 30% Matrigel. At
the time of cell injection, OHT (100 mg per 100ml in peanut oil) was delivered via
intraperitoneal injection every other day. When the tumours reached B150mm3
in volume, the mice were randomly separated into four groups and treated with
OHTþ polyethylene glycol 300 (PEG), oil (OHT removed)þPEG, OHTþVX-
680 or oil (OHT removed)þVX-680, respectively, via intraperitoneal injection.
VX-680 was prepared in a vehicle of 50% PEG in PBS and was administered at a
dose of 40mg kg 1. The tumour volumes were determined using calipers to
measure the longest (length) and shortest (diameter) every other day and were
calculated according to the standard formula (length diameter2 0.52). Next, the
tumour samples were harvested from killed mice and were processed for single-cell
suspension preparation and IHC analysis.
Flow cytometric analysis. Anti-Human/Mouse CD44 FITC (eBioscience) and
Anti-Human CD24 PerCP-eFluor 710 (eBioscience), Anti-Human CD24 PE
(eBioscience) and Anti-Human CD326 (EpCAM) PerCP-eFluor 710 (eBioscience)
were used for ﬂow cytometric analysis. Cells were harvested by trypsinization and
washed once in cold PBS. Next, cells were counted and resuspended in cold PBS at
a concentration of 1 106 cells per 100ml. Staining was performed by incubating
100 ml cells with 5 ml antibody on ice for 30min.
Cell sorting. For ﬂow cytometric cell sorting, the cells were dissociated into
single-cell suspensions, followed by labelling with Anti-Human CD24
PerCP-eFluor 710 (eBioscience). Next, the labelled cells or ﬂuorescent
protein-expressed cells were physically sorted by using a FACS ﬂow cytometer
(Beckman). The enrichment was conﬁrmed by ﬂow cytometric analysis.
For side population sorting, cells were resuspended in 37 C DMEM medium
containing 2% fetal bovine serum at a density of 1 106 cells per ml. Cells were
incubated with 5 mgml 1 Hoechst 33342 (Sigma) in the presence or absence of
50 mM verapamil (Sigma) for 1.5 h at 37 C in darkness with intermittent shaking.
Next, cells were washed twice with PBS and resuspended in PBS for ﬂow cytometric
sorting. Cell sorting was performed on a FACS ﬂow cytometer (Beckman).
Lentivirus preparation and transfection. Lentivirus was produced in 293T cells
using the second-generation packaging system plasmids psPAX2 (Addgene) and
pMD2.G (Addgene). One 10-cm culture dish containing 5 106 293T cells was
transfected using Lipofectamine 2000 (Life) with 12 mg lentiviral vector, 9 mg
psPAX2 and 3 mg pMD2.G. Supernatants were collected every 24 h between 24 and
72 h after transfection, pulled together and concentrated via ultracentrifugation,
and the viral titre was determined by serial dilutions. The multiplicity of infection
during transfection was 5.
Mammosphere culture. Single-cell suspension was obtained by trypsinization and
sieving through a 40-mm sieve and single cellularity was examined via microscopy.
Single cells were plated at a density 1 103 cells per ml in ultralow attachment
six-well plates (Corning). The cells were cultured in medium consisting of
DMEM/F12 (Gibco), supplemented with B27 (Life Technologies), 20 ngml 1
epidermal growth factor (Sigma-Aldrich), 20 ngml 1 basic ﬁbroblast growth
factor (BD Biosciences) and 4 mgml 1 heparin (Sigma-Aldrich) for 9–12 days. For
evaluation, the mammospheres were photographed under an inverted microscope
( 10objective, Olympus). The mammosphere diameters were analysed using
Image pro plus 6.0 software (Media Cybernetics).
Cytoplasmic/nuclear protein extraction. Cytoplasmic extracts were prepared by
resuspending the cell pellets in Buffer I, which contained 25mM HEPES pH 7.9,
5mM KCl, 0.5mM MgCl2 and 1mM dithiothreitol (DTT) for 5min. Next, an
equal volume of Buffer II containing 25mM HEPES pH 7.9, 5mM KCl, 0.5mM
MgCl2, 1mM DTT and 0.4% (v/v) NP40 supplemented with protease and
phosphatase inhibitors was added and the samples were incubated with rotation at
4 C for 15min. The lysates were centrifuged for 5min at 4 C at 2,500 r.p.m. in a
microfuge. Next, the supernatants were transferred to new Eppendorf tubes. The
pellets were rinsed once with Buffer II and the wash transferred to cytoplasmic
protein. The lysates were centrifuged again for 5min at 4 C at 10,000g, to remove
the residual nuclei. Next, the supernatants were transferred to new Eppendorf
tubes.
To obtain nuclear extracts, the pellets from the cytoplasmic extraction were
treated with Buffer III containing 25mM HEPES pH 7.9, 400mM NaCl, 10%
sucrose or dextrose, 0.05% NP-40 and 1mM DTT supplemented with protease and
phosphatase inhibitors. After rotating for 1 h at 4 C, the lysates were centrifuged
for 10min at 4 C, at 10,000g. Supernatants after this spin contained the nuclear
protein preparation.
Dual-luciferase reporter assays. Luciferase activity was measured using the
Dual-Luciferase Reporter Assay system (Promega) according to the manufacturer’s
instructions. Growth media were removed and cells were washed with PBS. Passive
lysis buffer (Promega) 500ml per well was added with gentle rocking for 15min at
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RT. Ten microlitres of lysate were transferred in black 96-well plate (Thermo).
Fireﬂy and Renilla luciferase activity were assayed sequentially to the cell lysate in
each well. For each luminescence reading, there would be a 2-s pre-measurement
delay after injector dispensing assay reagents into each well, followed by a 10-s
measurement time. Transcriptional activity was calculated as the ratio of ﬁreﬂy
luciferase activity (reporter) to Renilla luciferase activity (control).
ChIP and re-ChIP assays. ChIP was performed using ChIP-IT Express Chromatin
Immunoprecipitation Kits (Active Motif) according to the manufacturer’s protocol.
Brieﬂy, 1 107 cells, which were treated with the conditions described in the ﬁgure
legends or Supplementary Figurelegends, were ﬁxed with 1% formaldehyde for
10min at RT. Next, the cells were washed twice with PBS at 4 C, collected and
resuspended in ice-cold lysis buffer and lysed on ice for 30min. The cells were
homogenized on ice, to aid in nuclei release. Cells were sonicated ﬁve times for 5 s
at 50% of maximal power (Fisher Sonic Dismembrator). The chromatin (25mg)
was immunoprecipitated for 12 h with 2 mg of speciﬁc antibodies against AURKA
(Millipore), hnRNP K (Cell Signaling) or IgG (rabbit, Santa Cruz) and Protein G
magnetic beads (25 ml). Beads were then washed sequentially for 5min with the
following buffers: ChIP Buffer I for one time and ChIP Buffer II for two times. The
immune complexes were eluted with 50 ml elution buffer AM2. The supernatants
were reverse cross-linked by heating at 65 C for 12 h, treated with 1 ml RNaseA at
37 for 15min and digested with 2 ml proteinase K at 37 C for 1 h. DNA was
obtained by phenol and phenol/chloroform extractions. The human MYC
promoter-speciﬁc primers used for PCR were 50-GTCAAACAGTACTGCTA
CGG-30 (forward) and 50-TTCTTTTCCCCCACGCCCTC-30 (reverse). The primer
targeting a MYC gene exon was used as a negative control in these experiments.
MYC exon-speciﬁc primers were 50-GGATATCTGGAAGAAATTCGAGC-30
(forward) and 50-GATGAAGGTCTCGTCGTCCG-30 (reverse). Re-ChIP assays
were performed as described using the Re-ChIP-IT kit (Active Motif). Brieﬂy, the
precipitated chromatin from the ﬁrst ChIP reaction was eluted by 100 ml diluted
Re-ChIP-IT elution buffer at RT for 30min. Next, the eluted precipitate was
desalted by the desalting column provided in the kit. The second ChIP was
performed with 25ml Protein G magnetic beads, 90ml desalted chromatin and
2 mg second antibody. Next, the second precipitate was washed, eluted and
reverse cross-linked as in the ﬁrst ChIP. DNA was obtained by phenol and
phenol/chloroform extractions, and subjected to real-time PCR evaluation.
IHC and scoring. Antigen retrieval was performed by heating the sample in EDTA
buffer (pH 8.0) in a microwave oven for 15min. The slides were stained for 25min
at RT. EnVision Detection Systems (Dako) was used to detect antigen expression.
The IHC staining was quantiﬁed as the H-score, which has been validated for
breast cancer IHC staining56. The images were acquired using a Nuance EX
multispectral imaging system (PerkinElmer) under identical conditions; two ﬁelds
of each sample in the tissue microarray were acquired using a  20 objective.
Scoring was performed using inForm software (PerkinElmer). Typical images
corresponding to negative (four images, scored as ‘0’), weak (four images, scored as
‘1’), intermediate (four images, scored as ‘2’) and strong (four images, scored as ‘3’)
brown staining were selected by two independent experienced pathologist for
software training. During training, an algorithm, which helps the software to
distinguish between the cancer and non-cancer tissues, and distinguish between the
nuclear and cytoplasmic regions, and sets the thresholds for 0–3 staining, was
optimized. Next, the optimized algorithm was used to perform scoring of the other
samples. The H-score (between 0 and 300) for each sample was calculated in the
following way: (% of cells stained at intensity 1 1)þ (% of cells stained at
intensity 2 2)þ (% of cells stained at intensity 3 3). The receiver operating
characteristic curve analysis was used to select the cutoff point for each variable.
Semi-quantitative and quantitative PCR. Total RNA was extracted using
TRIzol reagent (Life Technologies) according to the manufacturer’s protocol.
Complementary DNA was synthesized by using M-MLV Reverse Transcriptase
(Life Technologies) according to the manufacturer’s instructions. Semi-quantitative
PCR was performed by using Premix Taq (Takara) according to the manufacturer’s
instructions. The primers used in semi-quantitative PCR were as follows: AURKA,
sense-50-GGAGAGCTTAAAATTGCAGATTTTG-30 , antisense-50-GCTCCAGAG
ATCCACCTTCTCAT-30 ; MYC, sense-50-TCAAGAGGCGAACACACAAC-30,
antisense-50-GGCCTTTTCATTGTTTTCCA; glyceraldehyde 3-phosphate
dehydrogense, sense-50-TGCCAAATATGATGACATCAAGAA-30 , antisense-
50-GGAGTGGGTGTCGCTGTTG-30 . The primers used in quantitative PCR
were shown in Supplementary Table 4.
Fluorescence resonance energy transfer. 293T cells were transiently transfected
with AURKA in the pEYFP-C1 vector (AURKA-EYFP) and hnRNP K in the
pECFP-C1 vector (hnRNP K-ECFP) using Lipofectamine 2000 (Life) according to
the manufacturer’s protocol. Fluorescence imaging was performed at RT 48 h after
transfection. Before ﬂuorescence recording, the culture media was replaced with a
solution containing 130mM NaCl, 5mM MgCl2, 2mM CaCl2, 5mM HEPES and
1mM EGTA (pH 7.4).
The FRET signals were determined as sensitized emission using a Leica
Advanced Wideﬁeld System AF7000 equipped with three FRET sets and a  63
glycerol immersion objective (numerical aperture 1.30). The FRET sets included
two external ﬁlter wheels, which facilitate high-speed FRET acquisition for each
ﬂuorophore excitation and emission wavelength, and one matching ﬁlter cube
equipped with a dichroic mirror (440:520). The excitation light was generated
using a 100-mW mercury lamp. The light intensity was controlled using a series of
neutral density ﬁlters installed in the external ﬁlter wheels. Fluorescence emission
was detected using a Hamamatsu electron multiplying charge-coupled device. For
FRET acquisition, three channels were deﬁned as follows: channel 1 for donor only
(donor excitation with donor emission); channel 2 for FRET (donor excitation
with acceptor emission); and channel 3 for acceptor only (acceptor excitation
with acceptor emission for yellow ﬂuorescent protein (YFP) cell imaging).
Straightforward correction was performed using both a donor-only reference and
an acceptor-only reference. The background value was determined from a region in
the recorded image that did not contain any cells. The FRET efﬁciency was
calculated as the enhanced YFP emission due to energy transfer
(E¼ acceptorsensitized emission/acceptordirect emission).
Molecular dynamics simulation. To obtain the protein structure of AURKA,
we predicted the structures of AURKA (1–125) and AURKA (390–403) using an
online I-TASSER server. Next, the predicted structure was assembled onto the
existing crystal structure of residues 126–389 (PDB:2J4F)57 to build the complete
structure. Similarly, we obtained the structure of the hnRNP K KI domain (residues
240–337). The conformation of the complexes formed between AURKA and
hnRNPK were predicted using Rossetta.
All simulations were carried out with Gromacs4.05 programme58. The
Gromos96(53a)59 force ﬁeld was used for the proteins and the TIP3P6 model for
the waters. In preparation for molecular dynamics simulation, the protein was
solvated using water pre-equilibrated at the appropriate temperature such that the
water box extended 10Å from the protein. Twenty-seven Cl anions were added
to neutralize the system. The staring structure was ﬁrst subjected to 1,000 steps of
steepest descent minimization and then heated to the 300 K with initial velocities
assigned form a Maxwellian distribution within 10 ns. In the following simulation,
bonds involving hydrogens were constrained with Lincs method60, thus permiting
an integration time step of 2 fs. The non-bonded interaction was cut off at 14Å,
whereas the electrostatic interaction beyond that was treated with particle mesh
Ewald method61. The charge-based neighbour list was updated every ten steps. The
system was maintained at 300 K and 1 bar using Berendsen coupling method62 with
a coupling frequency of every 0.5 and 0.1 ps, respectively. To ensure that the system
visits all possible minima, a production simulation of 2 ms was performed and the
trajectory was output every 100 ps for further analysis.
We obtained 2,000 conformations from the ﬁnal 1.0 ms after the equilibration
and performed analysis based on these snapshots. The interaction residues between
these two proteins for all the 2,000 conformations were determined by the
following criterion. If the shortest distance between any heavy atoms from two
residues belonging to two proteins was shorter than 4Å, then these two residues
from two proteins were considered to be the interaction residue pair. By counting
the pair and its corresponding interaction number, we saved the residue pairs if the
interaction occurs more than 1,000 times. These saved residue pairs were deﬁned as
the interface residues between these two proteins.
Bioinformatics analysis. For analysis using the Gene Expression Omnibus data
(accession code: GSE23541)63, the probes with detection P-values o0.01 in all
samples were excluded from the data set before analyses. If multiple probes
corresponded to the same gene, the expression values of these probes were
averaged. GSEAs64 were performed using GSEA v2.0.13 software (http://
www.broad.mit.edu/gsea) with 1,000 data permutations. The gene expression
signature were acquired from public research65–67 and GSEA website. Statistical
signiﬁcance was evaluated by means of false discovery rate (r0.25) and P-value
calculations (Po0.05).
For STRING (http://string-db.org/) analysis, differential expression genes were
subjected for analysing with default analysing parameters, except conﬁdenceZ0.7.
The raw data for STRING analysis were uploaded to NCBI (accession code:
GSE57931).
SILAC for identifying the interacting candidates of AURKA. Cells stably
expressing AURKA-Flag were cultured in SILAC labelling medium containing
107mg l 1 D3-leucine (heavy). The control cells (expressing Flag) were cultured in
SILAC labelling medium containing 105mg l 1 D0-leucine (light). After eight
passages, cells were lysed in RIPA. A 1:1 ratio of proteins from heavy and light
labelled cells was combined and immunoprecipitated by using anti-Flag M2
agarose beads. The beads were washed in RIPA and eluted with buffer containing
200mM Tris-HCl pH 8.0, 0.2mgml 1 Flag peptide (Sigma). The eluted proteins
were separated via SDS–PAGE and in-gel trypsin digestion was performed. Liquid
chromatography tandem mass spectrometry was performed on a LTQ-Orbitrap
instrument (Thermo Electron Corporation). The data were analysed using the IPI
databases for human version 3.35 with BioWorks 3.2 software (Thermo Electron
Corporation). The peptide/protein ratios were calculated using the SILAC function
module of the BioWorks software package with the following settings: target
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residue at leucine, mass at 3.0188, mass tolerance at 0.01Da, minimum threshold at
10, no smoothing and run the calculation based on area.
S1 nuclease protection assay. The DNA probes used to detect MYC P1 and P2
transcripts were prepared using PCR DIG Probe Synthesis Kit (Roche). The probe
for MYC  340Bþ 510 (the site of P1 initiation designated þ 1) was used in
Fig. 2l–o, Fig. 4e and Supplementary Fig. 2n. The probe corresponding to exon2 of
B2M and its upstream 362 bp intron was used as control and was also used in
Fig. 2l–o, Fig. 4e and Supplementary Fig. 2n. The probe consisted of MYC
( 226Bþ 211) and ﬁreﬂy luciferase 1–400 bp was used in Fig. 4f. The
hybridization mixture contained 25 ngml 1 of probe, 15mg of total cellular RNA,
80% formamide, 400mM NaCl, 40mM PIPES (pH 6.4), 1mM EDTA. The
hybridization temperatures for the MYC probe and B2M were 58 C and 52 C,
respectively. The hybridization temperature for the probe of chimeric gene was
58 C. The hybridzation was terminated by adding 750U S1 nuclease (Life) and
digestion carried out at 37 C for 1 h.
Fluorescence in situ hybridization. Formalin-ﬁxed parafﬁn-embedded breast
cancer tissue microarrays were pretreated (Dewax/Proteolysis) by the ZytoLight
FISH-Tissue Implementation Kit (Zytovision) according to the manufacturer’s
protocol. The copy number ofMYC were detected by ZytoLight SPEC CMYC/CEN
8 Dual Color Probe (Zytovision). Speciﬁcally, denaturation was performed at 75 C
for 10min followed by hybridization overnight at 37 C. 4,6-Diamidino-2-
phenylindole /Antifade Solution was applied after hybridization according to the
protocol. Image acquisition and analysis of slides were performed in the confocal
microscope (OLYMPUS FV1000). The copy number of CMYC/CEN 8 was
determined according to the manufacturer’s instructions by green/red spots,
respectively.
Plasmids. pLVX-HA was constructed by replacing DsRed gene in pLVX-DsRed-
N1-Monomer (Clontech) with HA sequence. WT AURKA was ampliﬁed from
MDA-MB-231 cells and insert into pLVX-HA to construct pLVX-AurA(WT)-HA.
pLVX-AurA(KA)-HA and pLVX-AurA(KD)-HA were generated by site-directed
mutagenesis using pLVX-AurA(WT)-HA. NLS or NES were fused to the carboxy
and amino terminus of AURKA by PCR, then were inserted into pLVX-HA to
construct pLVX-NLS-AURKA and pLVX-NES-AURKA. AURKA (1–383 or
1–333) were inserted into pLVX-HA to construct pLVX-1–383-HA or
pLVX-1–333-HA.
HA-tagged ER was ampliﬁed from pBabe-puro-myc-ER (Addgene) and used to
displace DsRed gene in pLVX-DsRed-N1-Monomer to construct pLVX-HA-ER. C
terminus NES was added to WT, KA and KD AURKA by PCR and AURKA-NES
was inserted into pLVX-HA-ER to produce AURKA-ER (AER). NLS-fused
1–333 of AURKA were inserted into pLVX-HA-ER to construct pLVX-HA-ER-
NLS-1–333.
GAL4DBD were cloned from pM (Clontech) and inserted into pLVX-HA
to construct pLVX-GAL4DBD-HA. WT, KA and KD AURKA were inserted
into pLVX-GAL4-DBD-HA to construct pLVX-Gal4DBD-HA-AurA(WT),
pLVX-Gal4DBD-HA-AurA(KA) and pLVX-Gal4DBD-HA-AurA(KD).
Promoters ofMYC( 2,269/þ 516),MYC( 1,012/þ 516),MYC( 352/þ 516)
and MYC( 104/þ 516) were ampliﬁed from MDA-MB-231 genomic DNA and
inserted into pGL3-Basic (Clontech) to construct pGL3-Myc, pGL3-Myc( 1,012/
þ 516), pGL3-Myc( 352/þ 516) and pGL3-Myc( 104/þ 516). The CT element
was mutated by site-directed mutagenesis. MYC( 226/þ 211) was inserted in
pGL3-Basic to construct chimeric gene. CT element was mutated by site-directed
mutagenesis. MYC( 2,269/þ 516) was inserted into this plasmid to replace the
cytomegalovirus (CMV) promoter of pLVX-DsRed-N1-Monomer. pRL-TK was
purchased from Clontech. The GAL4DBD reporter, L8G5-Luc, was kindly provided
by Professor Eric Lam (Imperial College London).
hnRNP K was ampliﬁed from MDA-MB-231 cells and inserted into pCMV-HA
(Genechem) or pCMV-c-Flag (Beyotime) to construct pCMV-HA-hnRNPK
or pCMV-hnRNPK-c-Flag, respectively. pCMV-hnRNPK(SA)-c-Flag and
pCMV-hnRNPK(SD)-c-Flag were generated by site-directed mutagenesis. hnRNP
A1 was ampliﬁed from MDA-MB-231 cells and inserted into pCMV-c-Flag to
construct pCMV-hnRNPA1-c-Flag.
GST was ampliﬁed from pGEX-6P-3 (GE Healthcare) and replaced DsRed gene
in pLVX-DsRed-N1-Monomer to generate pLVX-GST. Truncated form of
AURKA and hnRNP K were inserted into pLVX-GST. Enhanced green ﬂuorescent
protein-fused full-length and truncated AURKA were purchased from
GenePharma. NLS deletion mutant of hnRNP K was purchased from GenePharma.
Statistical analysis. The statistical analysis was performed using SPSS version
16.0 (SPSS Inc.). The Kaplan–Meier method was used to predict survival. The
log-rank test was used to make statistical comparisons. Pearson’s correlation
test was used to examine the correlation between IHC marker stainings. The
Kruskal–Wallis test followed by Dunn’s multiple comparison test were used to
make a statistical comparison regarding mammosphere size distribution. The
unpaired Student’s t-test was used to compare two groups. Analysis of variance
followed by the least signiﬁcant difference test was used for multiple group
comparisons. Statistical signiﬁcance of tumour volumes was calculated via analysis
of variance with Dunnett’s multiple comparison tests. The level of signiﬁcance was
set at Po0.05.
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